carboplatin + cisplatin + etoposide + vindesine

This is a combination chemotherapy regimen consisting of four agents: carboplatin, cisplatin, etoposide, and vindesine. Carboplatin and cisplatin are platinum-based chemotherapeutic agents that form DNA crosslinks, leading to apoptosis in rapidly dividing cells. Etoposide is a topoisomerase II inhibitor that prevents DNA re-ligation during replication, resulting in cell death. Vindesine is a vinca alkaloid that inhibits microtubule assembly, disrupting mitosis. This combination aims to maximize antitumor activity by leveraging the synergistic effects and non-overlapping toxicities of these drugs. The regimen has been studied primarily in advanced malignancies such as small cell lung cancer (SCLC) and esophageal cancer[1][4]. The primary mechanism of action for each component targets different aspects of cell division or DNA integrity.